Vor Biopharma (NASDAQ:VOR) Director Ra Capital Management, L.P. Sells 25,027 Shares of Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 25,027 shares of the stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $28.11, for a total transaction of $703,508.97. Following the completion of the transaction, the director directly owned 1,401,226 shares of the company’s stock, valued at approximately $39,388,462.86. This trade represents a 1.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, October 20th, Ra Capital Management, L.P. sold 92,023 shares of Vor Biopharma stock. The shares were sold at an average price of $29.67, for a total transaction of $2,730,322.41.
• On Friday, October 17th, Ra Capital Management, L.P. sold 260,859 shares of Vor Biopharma stock. The shares were sold at an average price of $29.39, for a total transaction of $7,666,646.01.
• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The shares were sold at an average price of $29.45, for a total transaction of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The shares were sold at an average price of $30.55, for a total transaction of $1,569,139.65.

Vor Biopharma Stock Down 4.6%

VOR stock opened at $26.50 on Thursday. The firm has a 50 day simple moving average of $35.96. The firm has a market capitalization of $181.53 million, a price-to-earnings ratio of -0.10 and a beta of 2.07. Vor Biopharma Inc. has a 12 month low of $2.62 and a 12 month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) EPS for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Analyst Ratings Changes

Several research firms have recently commented on VOR. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Baird R W upgraded shares of Vor Biopharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 15th. Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and increased their price target for the company from $20.00 to $64.00 in a research report on Wednesday, October 15th. Zacks Research lowered shares of Vor Biopharma from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of Vor Biopharma in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vor Biopharma presently has a consensus rating of “Hold” and a consensus price target of $77.83.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently bought and sold shares of VOR. Money Concepts Capital Corp boosted its position in Vor Biopharma by 106.1% during the first quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new position in shares of Vor Biopharma in the 1st quarter valued at $100,000. Goldman Sachs Group Inc. boosted its holdings in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after purchasing an additional 58,247 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Vor Biopharma in the 1st quarter valued at $140,000. Finally, XTX Topco Ltd acquired a new position in shares of Vor Biopharma in the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.